Cerliponase Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Cerliponase Alfa: From CLN2 Disease to Scheie Syndrome
One-Sentence Summary
Cerliponase alfa is a recombinant human TPP1 enzyme replacement therapy originally developed for CLN2 disease (a form of neuronal ceroid lipofuscinosis / Batten disease). The TxGNN model predicts it may be effective for Scheie Syndrome (a subtype of MPS I), but this prediction is currently supported by 0 clinical trials and 0 publications, and the underlying mechanistic basis appears weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in evidence pack (drug not marketed in Norway). Based on the drug's known mechanism referenced in the repurposing rationale, cerliponase alfa is used for CLN2 disease (TPP1 enzyme deficiency) |
| Predicted New Indication | Scheie Syndrome |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for cerliponase alfa (original_moa = Data Gap). Based on information embedded in the repurposing rationale, cerliponase alfa is a recombinant human TPP1 (tripeptidyl peptidase 1) enzyme replacement therapy, specifically indicated to supplement the TPP1 enzyme deficient in CLN2 disease patients.
The top-ranked prediction, Scheie syndrome, is a mild form of Mucopolysaccharidosis type I (MPS I), caused by deficiency of alpha‑L‑iduronidase (IDUA) — a completely different enzyme with no substrate overlap with TPP1. The same pattern holds for most of the other top-10 candidates (Hurler syndrome, cholesteryl ester storage disease, Gaucher disease, Wolman disease): each is a distinct lysosomal storage disorder driven by a different causative enzyme (IDUA, LAL, glucocerebrosidase). The high TxGNN scores most likely reflect knowledge-graph proximity between lysosomal storage disorders as a disease class, rather than a validated enzymatic or pharmacological cross-reactivity.
One partial exception is worth flagging: rank 8, "juvenile myoclonic epilepsy, susceptibility to," was separately classified by the model as a Research Question rather than "Hold." Progressive myoclonic epilepsy is a well-known clinical feature of CLN2 disease itself, so this connection may reflect a genuine phenotype-level link between TPP1/CLN2 biology and epilepsy networks — though it still lacks any clinical trial or literature validation and should not be interpreted as evidence for Scheie syndrome (the top-ranked candidate).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
No Norway market authorizations are currently registered for cerliponase alfa (market_status: 未上市 / Not Marketed; total_licenses: 0).
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data are all flagged as Data Gaps in the evidence pack; TFDA label retrieval is listed as a Blocking data gap — DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but there is zero clinical trial or literature support for the top-ranked candidate (Scheie syndrome), and the mechanistic link is weak — Scheie syndrome and CLN2 disease are driven by entirely different enzymes (IDUA vs. TPP1) with no known substrate overlap. This pattern of graph-proximity-without-mechanism repeats across 9 of the top 10 candidates, indicating the prediction reflects disease-class clustering rather than a validated biological hypothesis.
To proceed, the following is needed:
- TFDA/label warnings and contraindications (DG001, Blocking) — required before any S1 safety pre-assessment can begin
- Verified mechanism of action data from DrugBank (DG002, High priority) — needed to properly assess mechanistic plausibility
- If pursuing further, prioritize the rank 8 "juvenile myoclonic epilepsy" signal as a research hypothesis (phenotype-level link to CLN2 disease) rather than the top-ranked Scheie syndrome candidate, which currently has no mechanistic or empirical support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.